Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Souphiyeh Samizadeh & Koenraad De Boulle. (2018) Botulinum neurotoxin formulations: overcoming the confusion. Clinical, Cosmetic and Investigational Dermatology 11, pages 273-287.
Read now
Read now
Dirk Dressler & Hans Bigalke. (2017) Immunological aspects of botulinum toxin therapy. Expert Review of Neurotherapeutics 17:5, pages 487-494.
Read now
Read now
Kirsten E. Zeuner & Günther Deuschl. (2016) Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 457-466.
Read now
Read now
Roshan Kukreja & Bal Ram Singh. (2015) The botulinum toxin as a therapeutic agent: molecular and pharmacological insights. Research and Reports in Biochemistry 5, pages 173-183.
Read now
Read now
Sebastian Torres, Mark Hamilton, Elena Sanches, Polina Starovatova, Elena Gubanova & Tatiana Reshetnikova. (2014) Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clinical, Cosmetic and Investigational Dermatology 7, pages 11-17.
Read now
Read now
Mitchell F Brin, Charmaine James & John Maltman. (2014) Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics: Targets and Therapy 8, pages 227-241.
Read now
Read now
Welf Prager. (2013) Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clinical Pharmacology: Advances and Applications 5, pages 39-52.
Read now
Read now
Thomas Rappl, Daryousch Parvizi, Herwig Friedl, Maria Wiedner, Simone May, Bettina Kranzelbinder, Paul Wurzer & Bengt Hellbom. (2013) Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology 6, pages 211-219.
Read now
Read now
Carrie E Robertson & Ivan Garza. (2012) Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatric Disease and Treatment 8, pages 35-48.
Read now
Read now
Joohi Jimenez-Shahed. (2012) A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatric Disease and Treatment 8, pages 13-25.
Read now
Read now
Juwan Park, Michael S Lee & Andrew R Harrison. (2011) Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clinical Ophthalmology 5, pages 725-732.
Read now
Read now
Articles from other publishers (19)
Shavron Hada, Jae Chul Lee, Eun Chae Lee, Sunkyong Ji, Jeong Sun Nam, Bum Jin Yun, Dong Hee Na, Nam Ah Kim & Seong Hoon Jeong. (2022) Dissociation mechanics and stability of type A botulinum neurotoxin complex by means of biophysical evaluation. Journal of Pharmaceutical Investigation 52:4, pages 453-463.
Crossref
Crossref
Harald Hefter, Beyza Ürer, Raphaela Brauns, Dietmar Rosenthal, Sven G. Meuth, John-Ih Lee, Philipp Albrecht & Sara Samadzadeh. (2022) Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure. Toxins 14:1, pages 44.
Crossref
Crossref
Napamon Supornpun, Paisal Rummaneethorn, Thamthiwat Nararatwanchai, Tawee Saiwichai & Sirinthip Chaichalotornkul. (2022) Incobotulinum toxin A with a one-year long-lasting effect for trapezius contouring and superior efficacy for the treatment of trapezius myalgia. Journal of Cutaneous and Aesthetic Surgery 15:2, pages 168.
Crossref
Crossref
Tomasz Grenda, Anna Grenda, Paweł Krawczyk & Krzysztof Kwiatek. (2021) Botulinum toxin in cancer therapy—current perspectives and limitations. Applied Microbiology and Biotechnology 106:2, pages 485-495.
Crossref
Crossref
Mark S. Nestor, David Arnold & Daniel Fischer. (2020) The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II. Journal of Cosmetic Dermatology 19:11, pages 2785-2804.
Crossref
Crossref
Jungtae Na, Esther Lee, Yu-jin Kim, Mi Ji Choi, Su-Young Kim, Jeong Sun Nam, Bum Jin Yun & Beom Joon Kim. (2020) Long-term efficacy and safety of a new botulinum toxin type A preparation in mouse gastrocnemius muscle. Toxicon 187, pages 163-170.
Crossref
Crossref
Yuttana Srinoulprasert & Rungsima Wanitphakdeedecha. (2020) Antibody‐induced botulinum toxin treatment failure: A review and novel management approach. Journal of Cosmetic Dermatology 19:10, pages 2491-2496.
Crossref
Crossref
David Rupp, Greg Nicholson, David Canty, Joanne Wang, Catherine Rhéaume, Linh Le, Lance E. Steward, Mark Washburn, Birgitte P. Jacky, Ron S. Broide, Wolfgang G. Philipp-Dormston, Mitchell F. Brin & Amy Brideau-Andersen. (2020) OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays. Toxins 12:6, pages 393.
Crossref
Crossref
Debraj Shome, Rinky Kapoor & Stuti Khare. (2019) Two different types of botulinum toxins: Is there a difference in efficacy and longevity?. Journal of Cosmetic Dermatology 18:6, pages 1635-1641.
Crossref
Crossref
Steven Bellows & Joseph Jankovic. (2019) Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 11:9, pages 491.
Crossref
Crossref
Laure Mathevon, Arnaud Declemy, Isabelle Laffont & Dominic Perennou. (2019) Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review. Annals of Physical and Rehabilitation Medicine 62:4, pages 241-251.
Crossref
Crossref
Dong‐ho Bak, Mi Ji Choi, Esther Lee, Tae‐Rin Kwon, Jong Hwan Kim, Sang‐Hyun Nam, Kyoung‐Yun Kim, Seung Won Ahn, Seog‐Kyun Mun, Jungtae Na & Beom Joon Kim. (2018) A comparison study of prabotulinumtoxinA vs onabotulinumtoxinA in myostatin‐deficient mice with muscle hypertrophy. Basic & Clinical Pharmacology & Toxicology 124:4, pages 491-499.
Crossref
Crossref
Ioana Ion, Dimitri Renard, Anne Le Floch, Marie De Verdal, Stephane Bouly, Anne Wacongne, Alessandro Lozza & Giovanni Castelnovo. (2018) Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine. Toxins 10:6, pages 221.
Crossref
Crossref
Hyun-Mi Oh, Joo Park, Dae Song & Myung Chung. (2015) Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins. Toxins 8:1, pages 4.
Crossref
Crossref
Alberto Albanese, Giovanni Abbruzzese, Dirk Dressler, Wojciech Duzynski, Svetlana Khatkova, Maria Jose Marti, Pablo Mir, Cesare Montecucco, Elena Moro, Michaela Pinter, Maja Relja, Emmanuel Roze, Inger Marie Skogseid, Sofiya Timerbaeva & Charalampos Tzoulis. (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology 262:10, pages 2201-2213.
Crossref
Crossref
L. Ricciardi, F. Bove & A. Fasano. (2013)
Xeomin
®
use in patients with systemic immune reactions to other botulinum toxins type A
. European Journal of Neurology 20:3.
Crossref
Crossref
M. Brown, G. Nicholson, M. C. Ardila, A. Satorius, R. S. Broide, K. Clarke, T. Hunt & J. Francis. (2012) Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. Journal of Neural Transmission 120:2, pages 291-298.
Crossref
Crossref
Arne C. Rodloff & Monika Krüger. (2012) Chronic Clostridium botulinum infections in farmers. Anaerobe 18:2, pages 226-228.
Crossref
Crossref
D. Dressler. (2011)
Five‐year experience with incobotulinumtoxinA (Xeomin
®
): the first botulinum toxin drug free of complexing proteins
. European Journal of Neurology 19:3, pages 385-389.
Crossref
Crossref